Data Analytics in Pathology

Brian Jackson, MD, MS

VP, CMIO, ARUP Laboratories

Assoc Prof of Pathology (Clinical), University of Utah





Notice of Faculty Disclosure

In accordance with ACCME guidelines, any individual in a position to influence and/or control the content of this ASCP CME activity has disclosed all relevant financial relationships within the past 12 months with commercial interests that provide products and/or services related to the content of this CME activity.

The individual below has responded that he/she has no relevant financial relationship(s) with commercial interest(s) to disclose:

Brian Jackson, MD



Flexner Report (2010)

- Established <u>science</u> as foundation of medical training
- Created cultural divide between physicians (science) and administrators (business)



Role of the Clinical Laboratory

Historic: Run Tests

Future: <u>Diagnose Patients</u>






Ensuring Effective Diagnostics:

What Data and Metrics does the Clinical Enterprise Need?





Analogy: Managing a Company



Quality	Revenue	Costs
Key rollup measure(s)	Sales	Total costs
Defects by category	Market share Revenue by segment	Labor Supplies Depreciation
Defects by process	Revenue per sales rep	Detailed costs per department




Managing Diagnostics

Executive
^
•
Front line

Quality	Patient Benefit	Costs
Overall health system reliability	Global benefit	Total cost to lab
Per clinical practice unit	Benefit per test	Cost per test
Per test:TATAccuracyProcess quality	 Benefit per case Variation Consistency with guidelines Consistency w/expert opinion 	Cost per case



Managing Diagnostic Test Utilization





Total Cost of Laboratory Operations

- Labor
- Reagents
- Instruments
- Facility overhead
 - Space, utilities, IT, etc.





Cost per Test

- Proper Approach
 - Labor, reagents, instruments, overhead
- Do not use 3rd party fee schedule!
- Do not use chargemaster!





Cost per Case

- Assumes you have valid costs at component level
- Overhead allocation is tricky
- Dependent on the clinical algorithms





How to Solve The Cost Crisis In Health Care

The biggest problem with health care isn't with insurance or politics. It's that we're measuring the wrong things the wrong way.

by Robert S. Kaplan and Michael E. Porter

Harvard Business Review Sept 2011





Managing Diagnostic Test Utilization

Quality Costs **Patient Benefit** Overall health Global benefit Total cost to Executive system reliability ab Per clinical Benefit per test Cost per test practice unit Cost per case Benefit per case Per test: TAT **Variation** Consistency Accuracy Front line with guidelines Process quality Consistency w/expert opinion



Global Measures of Healthcare Quality?

Program	# Measures	# Diagnostic	# Lab
HEDIS	74	20	9
CMS ACO	33	13	4
Choosing Wisely	135	90	21



Patient Benefit per Test

- Function of how the test is used
 - NOT an intrinsic quality of the test itself
- Example: H pylori testing
 - Do stool Ag and breath test provide more patient value than serology?
 - Answer: Depends on the rate of endoscopy

Holmes et al. BDM Health Services Research 2010, 10:344





Patient Benefit (of a Test) per Case

- Outcomes
 - Generally not practical in this setting.
- Normative (Evidence Based Medicine)
 - Guidelines
 - Other clinical literature
 - Local expert opinion
- Non-normative/Descriptive
 - Variation






Diagnostic Testing Guidelines

Useful where available, but <u>extremely</u> incomplete






HPV: Tests on Patients <21 years old





HPV: Median Repeat Interval Following Negative Result






Measuring Variation

- Available across full spectrum of tests and settings
- Non-judgmental (Validity harder to question)
- Decades of experience (esp. Dartmouth)






Hospital Care Intensity (www.dartmouthatlas.org)





NMR Lipoprofile

Volume Index (normalized by ARUP volume)





4.1 to 37.0

37.1 to 340.0


340.1 to 6,074.0





VAP Cholesterol

Volume Index (normalized by ARUP volume)





1.7 to 10.1

10.2 to 49.7

49.8 to 566.0





Whole Blood Drug of Abuse Screens

- Hospital represented 0.3% of ARUP's reference work
- Ordered ~95% of ARUP's whole blood drug screens
 - ~\$70K/year
- Why?





Measuring Variation

- Comparison group needs to be "reasonably" valid
- Can benchmark on multiple levels
 - Physician group
 - Hospital
 - Health system
 - Geographic region
- Use raw volumes, <u>not</u> CPT, charges or costs





Managing Diagnostic Test Utilization

	Quality	Patient Benefit	Costs
Executive	Overall health system reliability	Global benefit	Total cost to lab
	Per clinical practice unit	Benefit per test	Cost per test
Front line	Per test: • TAT • Accuracy • Process quality	 Benefit per case Variation Consistency with guidelines Consistency w/expert opinion 	Cost per case



Where Do We Have Good Metrics Today?

Executive

Tront line

Quality	Patient Benefit	Costs
Overall health system reliability	Global benefit	Total cost to lab
Per clinical practice unit	Benefit per test	Cost per test
Per test:TATAccuracyProcess quality		



Where Are the Opportunities?

Executive

Tront line

Quality	Patient Benefit	Costs
Overall health system reliability	Global benefit	Total cost to lab
Per clinical practice unit	Benefit per test	Cost per test
	 Benefit per case Variation Consistency with guidelines Consistency w/expert opinion 	Cost per case







